The US Food and Drug Administration (FDA) has approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either previously untreated (first-line) or previously treated (relapsed or refractory) CD20-positive chronic lymphocytic leukemia (CLL).
22/02/2010
Roche has announced the results of a phase III trial investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone.
18/03/2010
THE COMMITTEE for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux (cetuximab) in combination with platinum-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, advanced or metastatic nonsmall cell lung cancer (NSCLC).
28/07/2009
THE Blanchette Rockefeller Neurosciences Institute (BRNI) has received a green light from the FDA to enter Phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease patients.
24/04/2009
Women with HER2-positive breast tumours (ie. tumours that produce too much of the HER2 protein) that are 1cm or smaller have a higher risk of their disease returning within 5 years than women with similarly small HER2-negative tumours. This finding from two retrospective studies published in the Journal of Clinical Oncology this month may shed some light on whether women with early stage, HER2-positive tumours should receive post-surgical (adjuvant) treatment.
05/11/2009
PRIMA Biomed has secured $12m in funding to advance the commercialisation of the CVac ovarian cancer vaccine treatment product.
17/03/2009
MESOBLAST has announced that it has successfully implanted the first five bone marrow transplant patients as part of its Phase I/II trial.
25/06/2009
New Australian start-up company WarraPharm is set to commercialise a suite of anti-cancer reformulations developed by researchers at the University of Wollongong (UOW).
09/11/2009
DR CHRISTOPHER Thornton form the University of Exeter has identified a quicker, cheaper and more accurate test for deadly Aspergillus fumigatus fungal infections in patients with damaged or suppressed immune systems.
07/04/2009
A STUDY released by the Translational Genomics Research Institute (TGen) has claimed cancer patients are able to survive longer under treatments based on their individual genetic profiles.
21/04/2009